>97%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
<0.10 EU per 1 μg of the protein by the LAL method.
12.4 kDa & 12.3 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
MIF (or macrophage migration inhibitory factor) was the first lymphokine/cytokine to be recognized in the pregenomics era (1, 2). Regardless, it is one of the least understood of all inflammatory mediators (1, 3). Human MIF is a 12.5 kDa, 115 amino acid (aa) nonglycosylated polypeptide that is synthesized without a signal sequence (4 - 7). Secretion occurs nonclassically via an ABCA1 transporter (8). The initiating Met is removed, leaving Pro as the first amino acid. The molecule consists of two alpha -helices and six beta -strands, four of which form a beta -sheet. The two remaining beta -strands interact with other MIF molecules, creating a trimer (2, 9, 10). Structure-function studies suggest MIF is bifunctional with segregated topology. The N- and C-termini mediate enzyme activity (in theory). Phenylpyruvate tautomerase activity (enol-to-keto) has been demonstrated and is dependent upon Pro at position #1 (11). Amino acids 50 - 65 have also been suggested to contain thiol-protein oxidoreductase activity (12). MIF has proinflammatory cytokine activity centered around aa’s 49 - 65. On fibroblasts, MIF induces, IL-1, IL-8 and MMP expression; on macrophages, MIF stimulates NO production and TNF-alpha release following IFN-gamma activation (13, 14). MIF apparently acts through CD74 and CD44, likely in some form of trimeric interaction (15, 16). Human MIF is active on mouse cells (14). Human MIF is 90%, 94%, 95%, and 90% aa identical to mouse, bovine, porcine and rat MIF, respectively.
Norand, E.F. and M. Leech (2005) Front. Biosci. 10:12.
Donn, R.P. and D.W. Ray (2004) J. Endocrinol. 182:1.
Calandra, T. and T. Roger (2003) Nat. Rev. Immunol. 3:791.
Kozak, C.A. et al. (1995) Genomics 27:405.
Weiser, W.Y. et al. (1989) Proc. Natl. Acad. Sci. USA 86:7522.
Paralkar, V. and G. Wistow (1994) Genomics 19:48.
Wistow, G.J. et al. (1993) Proc. Natl. Acad. Sci. USA 90:1272.
Flieger, O. et al. (2003) FEBS Lett. 551:78.
Philo, J.S. et al. (2004) Biophys. Chem. 108:77.
Sun, H-W. et al. (1996) Protein Eng. 9:631.
Stamps, S.L. et. al. (2000) Biochemistry 39:9671.
Nguyen, M.T. et al. (2003) J. Biol. Chem. 278:33654.
Sato, A. et al. (2003) Dev. Comp. Immunol. 27:401.
Bernhagen, J. et al. (1994) Biochemistry 33:14144.
Leng, L. et al. (2003) J. Exp. Med. 197:1467.
Meyer-Siegler, K.L. and P.L. Vera (2005) J. Urol. 173:615.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our Recombinant Human MIF Protein and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.